ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARP Annual Meeting 2019

Abstract Number: 1281

Maintenance Therapy for anti-MDA5-Positive Dermatomyositis Patients with Interstitial Lung Disease: Can They Achieve Drug-Free Remission?

Tsuneo Sasai1, Ran Nanashima 1, Tsuneyo Mimori 2, Hideaki Tsuji 1, Shuji Akizuki 1, Kosaku Murakami 3, Motomu Hashimoto 3, Hajime Yoshifuji 1, Masao Tanaka 2 and Koichiro Ohmura 2, 1Kyoto University, Kyoto, Japan, 2Graduate School of Medicine, Kyoto University, Kyoto, Japan, 3Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARP Annual Meeting 2019

Keywords: Idiopathic Inflammatory Myopathies (IIM) and interstitial lung disease

Session Information

Date: Monday, November 11, 2019

Title: Muscle Biology, Myositis & Myopathies Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Interstitial lung disease (ILD) accompanied by anti-melanoma differentiation associated gene 5 (MDA5)-positive dermatomyositis (DM) is often rapidly progressive and associated with poor life prognosis in Japanese patients. Recently, combined immunosuppressive therapy such as high-dose glucocorticoid (GC), calcineurin inhibitor (CNI), and intravenous cyclophosphamide (IVCY) has been suggested to be so effective that the prognosis has been improved. However, after achieving remission, appropriate maintenance therapy is still unclear. In this study, we evaluated the effect of induction therapy on maintenance therapy and looked into the possibility of drug-free remission.

Methods: We retrospectively examined the medical records of 86 anti-MDA5-positive adult DM-ILD patients in Kyoto university hospital. There were 57 patients who had achieved remission and survived more than 6 months. According to the induction treatment, we classified into 3 groups, Group A (n=37); simultaneous triple combination therapy (GC, CNI and IVCY with all drugs started within a week), Group B (n=8); step-up triple combination therapy (initiation of IVCY delayed up to 3 month)) and Group C (n=12); mono/dual-therapy (GC with or without CNI). We compared the recurrence rates by using log-rank test. We also compared the maintenance dose of GC at 36 months since initial treatment and the rates of drug free patients.

Results: The recurrence rates of Group A, B and C were not significantly different (p=0.07, log-rank test). The recurrence rates at 36 months since initial treatment were 0%, 0%, 19%, respectively (Figure 1). The dose of GC in Group A, B and C were 3.4±2.2 vs 4.0±1.2 vs 6.3±2.2 mg/day, respectively (p< 0.05, Kruskal-Wallis test). Although the drug free rates from GC were not significantly different (13% vs 0% vs 0%, p=0.07, Figure 2), the CNI free rates of Group A were significantly higher than that of Group C (43% vs 0%, p< 0.01 with Bonferroni correction, Figure 3).

Conclusion: Triple combined immunosuppressants for induction therapy could reduce the maintenance dose of immunosuppressants and the risk of recurrence in anti-MDA5-positive DM-ILD. Moreover, initial combination therapy might lead some patients to achieve drug-free remission.

Figure 1. Relapse-free survival rates -Kaplan-Meier-

Figure 2. Drug free rates from Glucocorticoid

Figure 3. Drug free rates from Calcineurin inhibitor


Disclosure: T. Sasai, None; R. Nanashima, None; T. Mimori, None; H. Tsuji, None; S. Akizuki, None; K. Murakami, Astellas Pharma Inc., 8, Bristol Myers Squibb,, 8, Chugai Pharmaceutical Co. Ltd., 8, Daiichi Sankyo Co. Ltd., 8, Eisai Co. Ltd, 8, Mitsubishi Tanabe Pharma Corporation, 8, Pfizer Inc, 8, UCB Japan Co. Ltd, 8; M. Hashimoto, Astellas, 8, Ayum, 9, Brystol-Meyers, 8, Chugai, 9, Tanabe-Mitsubishi, 8, 9, UCB Japan, 9; H. Yoshifuji, Astellas Pharma, 2, Chugai Pharmaceutical, 8; M. Tanaka, None; K. Ohmura, None.

To cite this abstract in AMA style:

Sasai T, Nanashima R, Mimori T, Tsuji H, Akizuki S, Murakami K, Hashimoto M, Yoshifuji H, Tanaka M, Ohmura K. Maintenance Therapy for anti-MDA5-Positive Dermatomyositis Patients with Interstitial Lung Disease: Can They Achieve Drug-Free Remission? [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/maintenance-therapy-for-anti-mda5-positive-dermatomyositis-patients-with-interstitial-lung-disease-can-they-achieve-drug-free-remission/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/maintenance-therapy-for-anti-mda5-positive-dermatomyositis-patients-with-interstitial-lung-disease-can-they-achieve-drug-free-remission/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology